Effect of chicoridin on ulcerative colitis

The efficacy of chicoridin in improvement of ulcerative colitis symptoms and patients' self-reported well-being

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190712044182N2

Enrollment

Registered

2019-12-30

Start date

2019-12-21

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis. Ulcerative colitis

Interventions

Intervention 1: Intervention group: Oral chicoridin, three capsules per day in three divided doses before meals for 8 weeks plus standard treatment for each patient as needed which at least includes o

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients 18-80 years old with mild to moderate ulcerative colitis based on Simple Clinical Colitis Activity Index

Exclusion criteria

Exclusion criteria: hospital admission significant comorbidities including liver or kidney diseases pregnancy lactating women

Design outcomes

Primary

Measure	Time frame
The efficacy of chicoridin in improvement of ulcerative colitis symptoms and patients' self-reported well-being according to the “Simple Clinical Colitis Activity Index” (SCCAI). Timepoint: 4weeks and 8 weeks after the intervention onset. Method of measurement: Interviews with patients and complete table of “Simple Clinical Colitis Activity Index” (SCCAI).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohsen Masoodi

Iran University of Medical Sciences

masoodi.m@iums.ac.ir+98 21 6655 3582

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026